Abstract:Adult-onset Still's disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still's disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the 'window of opportunity', new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.

Renal cell carcinoma presenting with brain metastasis from a 1.6 cm primary tumor.

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Clinical Characteristics and Outcome of Elderly Onset Adult-Onset Still?s Disease: A 10-Year Retrospective Study

Adult-Onset Still Disease Presenting With Dermatomyositis-Like Persistent Pruritic Lesions

Risk of Macrophage Activation Syndrome in Patients with Adult-Onset Still's Disease with Skin Involvement: A Retrospective Cohort Study

Clinical features and therapeutic response of adult onset Still's disease

Adult-onset Still's disease—pathogenesis, clinical manifestations, and new treatment options

Case Report: Adult Onset Still Disease in a 26-year-old Male

Case Report: A Rare Case of Elderly-Onset Adult-Onset Still’s Disease in a Patient With Systemic Lupus Erythematosus

[Effect of anionic detergents sodium dodecyl sulfate and alkylbenzyl sulfonate on adsorption and transport behavior of several enterotropic viruses in the soil under model conditions].

Hemophagocytic Syndrome Secondary to Adult-Onset Still's Disease but Very Similar to Lymphoma.

Adult-Onset Still's Disease (AOSD)—On the Basis of Own Cases

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

[Update on Adult-Onset Still's Disease: Diagnosis, Therapy and Guideline]

Ventilatory response to imagination of exercise and altered perception of exercise load under hypnosis.

Walter E. Stamm, MD, 1945-2009.

Unveiling the Mystery of Adult-Onset Still's Disease: A Compelling Case Report

Metabolomics: Budgeting on a diet.

Adult-onset Still's disease masquerading as acute coronary syndrome: a case report and review of the literature

Serosal Involvement in Adult-Onset Still's Disease: A Multicentre and Retrospective Study.

Clinical and immunological feature, therapeutic response and prognosis of adult onset Still's disease